Adhera Therapeutics (Adhera Therapeutics) 3-Year EBITDA Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics 3-Year EBITDA Growth Rate?

Adhera Therapeutics's EBITDA per Share for the three months ended in Sep. 2023 was $-0.68.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adhera Therapeutics was 81.70% per year. The lowest was -100.00% per year. And the median was 20.70% per year.

Competitive Comparison of Adhera Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Adhera Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adhera Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's 3-Year EBITDA Growth Rate falls into.

Adhera Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Adhera Therapeutics (OTCPK:ATRX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Adhera Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adhera Therapeutics (Adhera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Innovation Parkway, Baton Rouge, LA, USA, 70820

Website

https://www.adherathera.com

Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.

Executives

Zahed Subhan	director	8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness	director	8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: Chief Executive Officer	549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley	officer: SVP Finance & Accounting	5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan	director	812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague	officer: Chief Financial Officer	C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell	director	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato	officer: CEO	400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris	director	805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein	officer: Chief Legal Officer	C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah	officer: Chief Financial Officer	10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson	officer: Chief Commercial Officer	2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif	officer: Chief Operating Officer	21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679